<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096314</url>
  </required_header>
  <id_info>
    <org_study_id>PETAL02VIOLET</org_study_id>
    <secondary_id>1U01HL123009</secondary_id>
    <nct_id>NCT03096314</nct_id>
  </id_info>
  <brief_title>Vitamin D to Improve Outcomes by Leveraging Early Treatment</brief_title>
  <acronym>VIOLET</acronym>
  <official_title>Vitamin D to Improve Outcomes by Leveraging Early Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency is a common, potentially reversible contributor to morbidity and
      mortality among critically ill patients. We conducted a randomized, double-blind,
      placebo-controlled, phase 3 trial of early vitamin D3 supplementation in critically ill,
      vitamin D-deficient patients who were at high risk for death. Patients screened as vitamin D
      deficient (&lt;20 ng/mL) were randomized. Randomization occurred within 12 hours after the
      decision to admit the patient to an intensive care unit. Eligible patients received a single
      enteral dose of 540,000 IU of vitamin D3 or matched placebo. The primary end point was 90-day
      all-cause, all-location mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the efficacy and safety of early administration of vitamin D3
      (cholecalciferol) in reducing mortality and morbidity for vitamin D deficient patients at
      high risk for Acute Respiratory Distress Syndrome (ARDS) and mortality.

      Primary Hypothesis: Early administration of vitamin D3 (cholecalciferol) will improve
      all-cause, all-location mortality to day 90 in vitamin D deficient patients at high risk for
      ARDS and mortality.

      Methods: Patients were recruited from the emergency departments (EDs), hospital wards,
      operating rooms, intensive care unites (ICUs) and other acute care areas of the participating
      PETAL Network Clinical Centers. Screening included a test for Vitamin D (25OHD) levels using
      either the hospital's clinical laboratory or an FDA-approved point-of-care device (FastPack
      IP, Qualigen Inc). Patients screened as vitamin D deficient (&lt;20 ng/mL) were randomized. Half
      of the randomized patients received an early administration of high-dose vitamin D3 and the
      other half received a placebo. Both active and placebo products were given orally or via
      naso/orogastric tube.

      Rational: Vitamin D has pleiotropic roles in regulating immune function and maintaining
      epithelial surface integrity. Strong preclinical data support the protective role of vitamin
      D in regulating pulmonary inflammation and disruption of the alveolar-capillary membrane that
      are fundamental to ARDS pathogenesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause, All-location Mortality to Day 90</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Vital status of the patient at day 90 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause, All Location Mortality to Day 28</measure>
    <time_frame>Up to 28 days after randomization</time_frame>
    <description>This variable was calculated in participants who were reported alive at day 28. Vital status of the patient at day 28 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, or review of obituaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality to Day 90</measure>
    <time_frame>Up to 90 days after randomization</time_frame>
    <description>Analysis of the number of participants who died prior to hospital discharge up to study day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive and Home (Prior Level of Care) at Day 90</measure>
    <time_frame>90 days post randomization</time_frame>
    <description>This endpoint is the count of participants who have survived and are present at home, defined as pre-hospitalization level of care, at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay to Day 90</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Number of days from enrollment to the day of study hospital discharge up to day 90. Only calculated for patients that survived through day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Facility Length of Stay to Day 90</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Healthcare facility length of stay is the time spent in another hospital or healthcare facility (e.g. long-term acute care [LTAC] hospitals or acute rehabilitation/skilled nursing facility), for the subgroup of participants that were discharged to another healthcare facility after the initial hospitalization. This measure is defined as the number of days from initial hospital discharge to the first facility discharge to home (pre-hospitalization level of care) up to day 90. Healthcare facility LOS is zero for patients discharged to home (pre-hospitalization level of care) from the study hospital. This endpoint will be analyzed only in survivors using SACE methods because healthcare facility length of stay in those who die during the follow-up period is non-informative for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days (VFDs) to Day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>In participants who survive 28 days, ventilator free days (VFDs) is defined as 28 minus duration of ventilation. Duration of ventilation is counted from the first study day of assisted breathing through the last day of assisted breathing provided the last day is prior to day 28. Or it is counted from the first study day of assisted breathing through day 28. For participants discharged with assisted ventilation prior to day 28, a phone call will be required to assess ventilator status at day 28. Participants discharged prior to day 28 (but not to home) on unassisted breathing will be assumed to remain on unassisted breathing through day 28. Isolated periods of ventilation briefer than 24 hours for surgical procedures and ventilation solely for sleep disordered breathing do not count towards duration of ventilation. In participants who never require assisted breathing, duration of ventilation is zero. Participants who do not survive 28 days will be assigned zero VFD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life by EuroQol (EQ-5D-5L)</measure>
    <time_frame>baseline to study day 90</time_frame>
    <description>Changes in Quality of life score by EuroQol from baseline to day 90. Change was calculated as the value at day 90 minus the value at baseline. The EuroQol score is based on 5 dimensions of perceived problems: Mobility, Self-Care, Anxiety/Depression, Pain/discomfort, and Usual Activities. Problems with each area are assigned a level from 1-5 with level 1 being no problem and level 5 indicating extreme problems. A unique health state score is defined by combining 1 level from each of the 5 dimensions. Responses can be used to calculate a health utility score55 associated with the given health state that ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed (New) ARDS to Day 7</measure>
    <time_frame>Up to 7 days after randomization</time_frame>
    <description>Presence of ARDS determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio (i.e., imputed P/F ratio) and chest x-ray confirmation. PaO2 = partial pressure of arterial oxygen; FiO2 = percentage of inspired oxygen; SpO2 = peripheral capillary oxygen saturation, an estimate of the amount of oxygen in the blood. For participants with P/F &lt;300 or imputed P/F &lt;300, FiO2 ≥40%, and PEEP ≥5 cm H2O, we determined if hypoxemia was valid, acute, and not fully explained by congestive heart failure (CHF) or fluid overload. PEEP = positive end expiatory pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Acute Respiratory Distress Syndrome (ARDS)</measure>
    <time_frame>7 days after randomization</time_frame>
    <description>Severity of ARDS is determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio and confirmation of ARDS through chest x-ray reviews. The breakout of mild to severe was categorized as P/F or imputed P/F ratio of 201-300 (mild), 100-200 (moderate), or less than 100 (severe). This physiologic outcome is one of three key organ systems (respiratory, renal, and cardiovascular) used to assess change in organ failure severity from randomization up to study day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Acute Kidney Injury (AKI)</measure>
    <time_frame>Up to 7 days after randomization</time_frame>
    <description>This physiologic outcome is one of three key organ systems (respiratory, renal, and cardiovascular) used to assess change in organ failure severity from randomization up to study day 7. Worst AKI was determined by using highest daily creatinine values or new use of dialysis/ renal replacement therapy (chronic dialysis participants were excluded). Mild: On-study creatinine levels 1.5 times greater than baseline value or 0.3 mg/dL over the prehospital value. Moderate: On-study creatinine levels 2 times greater than the baseline pre-hospital value. Severe: On-study creatinine creatinine levels are 3 times greater than baseline prehospital value, or the on-study creatinine level is over 4 mg/dL with an acute (1 day) 0.5 mg/dL rise, or participant is on new renal replacement therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Renal Replacement Therapy (RRT)</measure>
    <time_frame>Up to 7 days after randomization</time_frame>
    <description>Participants who were on chronic dialysis at baseline were excluded from the analysis. Participants who started renal replacement therapy on a study day after day 0 and inclusive of day 7 were considered as having new renal replacement therapy. Those who have never started renal replacement therapy over days 0-7 were considered as not having new renal replacement therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Creatinine Levels</measure>
    <time_frame>Up to 7 days after randomization</time_frame>
    <description>The highest recorded creatinine values is taken from available levels reported across the 7 study days for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Vasopressor Use to Day 7</measure>
    <time_frame>Up to 7 days after randomization</time_frame>
    <description>The number of subjects in each arm that are started on a vasopressor after randomization up to study day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Cardiovascular SOFA (Sepsis Related Organ Failure Assessment) Score</measure>
    <time_frame>Up to 7 days after randomization</time_frame>
    <description>Cardiovascular score of the Organ SOFA score was used:
Score = 0: MAP* &gt;= 70 mmHg and No Drug;
Score = 1: MAP &lt; 70 mmHg and No Drug;
Score = 2: (Any MAP) ( dopamine&lt;=5 OR any dobutamine ) AND no other drugs (include neosynephrine vasopressin);
Score = 3: (Any MAP) 5 &lt; dopamine &lt;= 15 OR epinephrine &lt;= 0.1 OR norepinephrine &lt;= 0.1 OR neosynephrine &lt;=0.22 OR any dose vasopressin;
Score = 4: (Any MAP) dopamine &gt; 15 OR epinephrine &gt; 0.1 OR norepinephrine &gt; 0.1 OR neosynephrine &gt; 0.22
* MAP = mean arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25OHD Levels at Day 3</measure>
    <time_frame>3 days after randomization</time_frame>
    <description>Baseline levels will be measured using LC/MS/MS methods (all randomized participants) and at day 3 (the first 300 randomized participants only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Total Calcium to Day 14</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>Clinically available serum or ionized Ca levels were obtained through day 14 for all randomized patients. This time frame was selected to align with the 25OHD half life of two weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest Ionized Calcium to Day 14</measure>
    <time_frame>up to 14 days after randomization</time_frame>
    <description>Clinically available serum or ionized calcium levels through day 14 were collected for all randomized participants. This time frame was selected to align with the 25OHD half life of two weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalcemia to Day 14</measure>
    <time_frame>up to 14 days after randomization</time_frame>
    <description>As the half-life of 25OHD is approximately 2 weeks, clinically available serum or ionized calcium levels through study day 14 were collected. The number of participants with hypercalcemia was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney Stones to Day 90</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Incident of kidney stones determined by chart review at the end of hospitalization and by self-report at day 90 phone call in those discharged from the hospital prior to day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fall-related Fractures to Day 90</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>Incident of fall-related fractures will be determined by chart review at the end of hospitalization and by self-report at day 90 phone call for those discharged from the hospital prior to day 90. Most data suggest that high dose vitamin D in healthy outpatients may improve muscle function, balance, and bone mineral density, and thus decrease fall-related fractures, but other data suggest that high dose vitamin D supplementation may actually increase the incidence of falls/fractures. Because of this uncertainty and limited data in hospitalized patients, we assessed for incident of fall-related fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Falls to Day 90</measure>
    <time_frame>90 days post randomization</time_frame>
    <description>We assessed for incidence of falls by chart review at the end of hospitalization and by self-report at the 90 day phone call. Most data suggest that high dose vitamin D in healthy outpatients may improve muscle function, balance, and bone mineral density, and thus decrease fall-related fractures, but other data suggest that high dose vitamin D supplementation may actually increase the incidence of falls/fractures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1358</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>High dose vitamin D formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
    <arm_group_label>High dose vitamin D formulation</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Intention to admit to ICU from emergency department, hospital ward, operating room, or
             outside facility

          3. One or more of the following acute risk factors for ARDS and mortality contributing
             directly to the need for ICU admission:

             Pulmonary

               1. Pneumonia

               2. Aspiration

               3. Smoke Inhalation

               4. Lung contusion

               5. Mechanical ventilation for acute hypoxemic or hypercarbic respiratory failure
                  Extra-Pulmonary

               6. Shock

               7. Sepsis

               8. Pancreatitis

          4. Vitamin D deficiency (screening 25OHD level &lt;20 ng/mL)

        Exclusion Criteria:

          1. Inability to obtain informed consent

          2. Unable to randomize within 12 hours of ICU admission decision

          3. Unable to take study medication by mouth or enteral tube

          4. Baseline serum calcium &gt;10.2 mg/dL (2.54 mmol/L) or ionized calcium &gt;5.2 mg/dL (1.30
             mmol/L)

          5. Known kidney stone in past year or history of multiple (&gt;1) prior kidney stone
             episodes

          6. Decision to withhold or withdraw life-sustaining treatment (patients are still
             eligible if they are committed to full support except cardiopulmonary resuscitation if
             a cardiac arrest occurs)

          7. Expect &lt;48 hour survival

          8. If no other risk factors present, a) mechanical ventilation primarily for airway
             protection, pain/agitation control, or procedure; or b) elective surgical patients
             with routine postoperative mechanical ventilation; or c) anticipated mechanical
             ventilation duration &lt;24 hours; or d) chronic/home mechanical ventilation for chronic
             lung or neuromuscular disease (non-invasive ventilation used solely for
             sleep-disordered breathing is not an exclusion).

          9. Prisoner

         10. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boyd Taylor Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Del Norte</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Hospital East Campus</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian/Mercy/Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay-Dee Hospital</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://petalnet.org</url>
    <description>Website for the PETAL Network</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>January 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Boyd Taylor Thompson</investigator_full_name>
    <investigator_title>Co-Prinicipal Investigator PETAL CCC</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be collected electronically and stored at the Clinical Coordinating Center at Massachusetts General Hospital (MGH). A de-identified database of all data will be available for use 3 years after the primary publication. Data can be accessed at that point via the National Heart Lung Blood Institute (NHLBI) BioLINCC data and biospecimen repository.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03096314/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03096314/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>After initial study screening, eligible patients were consented and received secondary screening for vitamin D deficiency; performed via an FDA-approved test (either hospital clinical laboratory or the FastPack IP device (Qualigen Inc., Carlsbad, CA). Participants with a screening 25OHD level &lt;20 ng/mL were randomized for treatment assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose Vitamin D Formulation</title>
          <description>Patients at high risk for ARDS and mortality with initial screening 25OHD levels &lt; 20 ng/mL randomized to receive 540,00 IU vitamin D3 (cholecalciferol) as a single, liquid enteral dose, administered either orally or via naso/orogastric tube within 2 hours of randomization.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients at high risk for ARDS and mortality with initial screening 25OHD levels &lt; 20 ng/mL randomized to receive placebo (similar in appearance to the vitamin D3 treatment) as a single, liquid enteral dose, administered either orally or via naso/orogastric tube within 2 hours of randomization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screened Vitamin D Deficient</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="690"/>
                <participants group_id="P2" count="668">2 randomized but not included in analysis; 1 treated but inadequate consent and 1 withdrew.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="681"/>
                <participants group_id="P2" count="656"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Confirmed Vitamin D Deficient</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="538">Confirmed deficient (a prior primary analysis subgroup) is a subgroup of the screened deficient.</participants>
                <participants group_id="P2" count="540">Confirmed deficient (a prior primary analysis subgroup) is a subgroup of the screened deficient.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="531"/>
                <participants group_id="P2" count="528"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 1360 patients who screened as vitamin D deficient (all randomized) and received a confirmatory LC/MS/MS test (liquid chromatography tandem mass spectrometry). Subjects with a 25OHD result &lt;20 ng/L by LC/MS/MS were the confirmed deficient cohort and included in the primary analysis (N= 538 in Vit D Arm and N = 540 in Placebo arm).</population>
      <group_list>
        <group group_id="B1">
          <title>High Dose Vitamin D Formulation</title>
          <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="538"/>
            <count group_id="B2" value="540"/>
            <count group_id="B3" value="1078"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="368"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="747"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="467"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Non-Hispanic White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="567"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Black Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Available</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="540"/>
                    <measurement group_id="B3" value="1078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Facility residence prior to hospitalization (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health-related quality of life by EuroQol (EQ-5D-5L)</title>
          <description>The questionnaire provides a simple descriptive profile of a respondent’s health state. Index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health)</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" spread="0.3"/>
                    <measurement group_id="B2" value="0.7" spread="0.3"/>
                    <measurement group_id="B3" value="0.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson co-morbidity index</title>
          <description>The Charlson comorbidity index predicts the one-year mortality for a patient who may have a range of comorbid conditions, such as heart disease, AIDS, or cancer (a total of 22 conditions). Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. Index scores range from 0 to 37, with higher scores indicating more coexisting conditions.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="2.9"/>
                    <measurement group_id="B2" value="3.5" spread="6.5"/>
                    <measurement group_id="B3" value="3.7" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <population>Data missing on some subjects prevented calculating index on total cohort.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="524"/>
                    <count group_id="B2" value="529"/>
                    <count group_id="B3" value="1053"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="10.1"/>
                    <measurement group_id="B2" value="31.0" spread="11.4"/>
                    <measurement group_id="B3" value="30.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lung Injury risk factors number (%)</title>
          <description>Subjects may have more than one risk factor</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Pneumonia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shock</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mechanical ventilation for acute resp failure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspiration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung contusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical intensive care unit admission - (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="447"/>
                    <measurement group_id="B2" value="462"/>
                    <measurement group_id="B3" value="909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>The Sequential Organ Failure Assessment (SOFA) Score is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours until discharge using the worst parameters measured during the prior 24 hours. The score ranges from 0-24; a higher score indicates greater predicted mortality.</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="2.9"/>
                    <measurement group_id="B2" value="4.0" spread="3.1"/>
                    <measurement group_id="B3" value="4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lung injury prediction score (LIPS)</title>
          <description>The lung injury prediction score (LIPS) is a validated prediction model that uses clinical data at the time of presentation to the emergency department (ED) to identify patients at high risk for ARDS. The score is a sum of 19 components, each of which is assigned points. A score of zero = no lung injury. Missing values are given a value of zero. The score ranges from 0 to 36, with higher scores indicating a higher risk of lung injury (as described in Gajic AJRCCM 2020; PMID 20802164).</description>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="2.9"/>
                    <measurement group_id="B2" value="5.3" spread="3.1"/>
                    <measurement group_id="B3" value="5.3" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mechanical Ventilation (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ARDS (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vasopressor use at baseline (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D supplement use in past week (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multivitamin use in past week (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated average daily vitamin D dose</title>
          <population>This variable was analyzed in those participants that received a multivitamin/supplement within 30 days prior to current study hospitalization.</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="57"/>
                    <count group_id="B2" value="54"/>
                    <count group_id="B3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3269" spread="13118"/>
                    <measurement group_id="B2" value="4252" spread="15094"/>
                    <measurement group_id="B3" value="3747.1" spread="14057.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-hydroxyvitamin D</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="538"/>
                    <count group_id="B2" value="540"/>
                    <count group_id="B3" value="1078"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" spread="4.8"/>
                    <measurement group_id="B2" value="11" spread="4.7"/>
                    <measurement group_id="B3" value="11.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total serum calcium (mg/dL)</title>
          <population>This outcome was analyzed in participants in the confirmed deficient cohort with available serum calcium levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="528"/>
                    <count group_id="B2" value="526"/>
                    <count group_id="B3" value="1054"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.3" spread="0.9"/>
                    <measurement group_id="B2" value="8.3" spread="0.9"/>
                    <measurement group_id="B3" value="8.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ionized calcium (mg/dL)</title>
          <population>This outcome was analyzed in participants in the confirmed deficient cohort with available ionized calcium levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="210"/>
                    <count group_id="B2" value="212"/>
                    <count group_id="B3" value="422"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.3" spread="1.4"/>
                    <measurement group_id="B2" value="4.3" spread="0.9"/>
                    <measurement group_id="B3" value="4.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine (mg/dL)</title>
          <population>This outcome was analyzed in participants in the confirmed deficient cohort with available serum creatinine levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="535"/>
                    <count group_id="B2" value="539"/>
                    <count group_id="B3" value="1074"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="2.3"/>
                    <measurement group_id="B2" value="2.0" spread="2.0"/>
                    <measurement group_id="B3" value="2.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>The estimated glomerular filtration rate was calculated based on the following variables: race, sex, and serum creatinine using the formula: CFR = 166 x (Scr/0.7) -0.329 x (0.993) Age.</description>
          <population>This variable was analyzed in participants in the confirmed deficient cohort and calculated based on available data.</population>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="535"/>
                    <count group_id="B2" value="539"/>
                    <count group_id="B3" value="1074"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="39.3"/>
                    <measurement group_id="B2" value="60.9" spread="36.9"/>
                    <measurement group_id="B3" value="60.5" spread="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All-cause, All-location Mortality to Day 90</title>
        <description>Vital status of the patient at day 90 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI).</description>
        <time_frame>90 days after randomization</time_frame>
        <population>The primary analysis included subjects who had confirmed vitamin D deficiency by LC/MS/MS testing.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause, All-location Mortality to Day 90</title>
          <description>Vital status of the patient at day 90 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI).</description>
          <population>The primary analysis included subjects who had confirmed vitamin D deficiency by LC/MS/MS testing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="531"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Generalized linear model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause, All Location Mortality to Day 28</title>
        <description>This variable was calculated in participants who were reported alive at day 28. Vital status of the patient at day 28 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, or review of obituaries.</description>
        <time_frame>Up to 28 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause, All Location Mortality to Day 28</title>
          <description>This variable was calculated in participants who were reported alive at day 28. Vital status of the patient at day 28 was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, or review of obituaries.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="531"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Mortality to Day 90</title>
        <description>Analysis of the number of participants who died prior to hospital discharge up to study day 90.</description>
        <time_frame>Up to 90 days after randomization</time_frame>
        <population>Participant count is based on available data.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality to Day 90</title>
          <description>Analysis of the number of participants who died prior to hospital discharge up to study day 90.</description>
          <population>Participant count is based on available data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="538"/>
                <count group_id="O2" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alive and Home (Prior Level of Care) at Day 90</title>
        <description>This endpoint is the count of participants who have survived and are present at home, defined as pre-hospitalization level of care, at day 90.</description>
        <time_frame>90 days post randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Alive and Home (Prior Level of Care) at Day 90</title>
          <description>This endpoint is the count of participants who have survived and are present at home, defined as pre-hospitalization level of care, at day 90.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="528"/>
                <count group_id="O2" value="526"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay to Day 90</title>
        <description>Number of days from enrollment to the day of study hospital discharge up to day 90. Only calculated for patients that survived through day 90.</description>
        <time_frame>90 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay to Day 90</title>
          <description>Number of days from enrollment to the day of study hospital discharge up to day 90. Only calculated for patients that survived through day 90.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="9.2"/>
                    <measurement group_id="O2" value="10.4" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Facility Length of Stay to Day 90</title>
        <description>Healthcare facility length of stay is the time spent in another hospital or healthcare facility (e.g. long-term acute care [LTAC] hospitals or acute rehabilitation/skilled nursing facility), for the subgroup of participants that were discharged to another healthcare facility after the initial hospitalization. This measure is defined as the number of days from initial hospital discharge to the first facility discharge to home (pre-hospitalization level of care) up to day 90. Healthcare facility LOS is zero for patients discharged to home (pre-hospitalization level of care) from the study hospital. This endpoint will be analyzed only in survivors using SACE methods because healthcare facility length of stay in those who die during the follow-up period is non-informative for this endpoint.</description>
        <time_frame>90 days after randomization</time_frame>
        <population>This outcome was analyzed only in survivors using SACE methods because healthcare facility length of stay in those who die during the follow-up period is non-informative for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Facility Length of Stay to Day 90</title>
          <description>Healthcare facility length of stay is the time spent in another hospital or healthcare facility (e.g. long-term acute care [LTAC] hospitals or acute rehabilitation/skilled nursing facility), for the subgroup of participants that were discharged to another healthcare facility after the initial hospitalization. This measure is defined as the number of days from initial hospital discharge to the first facility discharge to home (pre-hospitalization level of care) up to day 90. Healthcare facility LOS is zero for patients discharged to home (pre-hospitalization level of care) from the study hospital. This endpoint will be analyzed only in survivors using SACE methods because healthcare facility length of stay in those who die during the follow-up period is non-informative for this endpoint.</description>
          <population>This outcome was analyzed only in survivors using SACE methods because healthcare facility length of stay in those who die during the follow-up period is non-informative for this endpoint.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="17.5"/>
                    <measurement group_id="O2" value="8.1" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days (VFDs) to Day 28</title>
        <description>In participants who survive 28 days, ventilator free days (VFDs) is defined as 28 minus duration of ventilation. Duration of ventilation is counted from the first study day of assisted breathing through the last day of assisted breathing provided the last day is prior to day 28. Or it is counted from the first study day of assisted breathing through day 28. For participants discharged with assisted ventilation prior to day 28, a phone call will be required to assess ventilator status at day 28. Participants discharged prior to day 28 (but not to home) on unassisted breathing will be assumed to remain on unassisted breathing through day 28. Isolated periods of ventilation briefer than 24 hours for surgical procedures and ventilation solely for sleep disordered breathing do not count towards duration of ventilation. In participants who never require assisted breathing, duration of ventilation is zero. Participants who do not survive 28 days will be assigned zero VFD.</description>
        <time_frame>28 days after randomization</time_frame>
        <population>Excludes subjects who never required assisted breathing or who did not survive 28 days (considered zero vent free days).</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days (VFDs) to Day 28</title>
          <description>In participants who survive 28 days, ventilator free days (VFDs) is defined as 28 minus duration of ventilation. Duration of ventilation is counted from the first study day of assisted breathing through the last day of assisted breathing provided the last day is prior to day 28. Or it is counted from the first study day of assisted breathing through day 28. For participants discharged with assisted ventilation prior to day 28, a phone call will be required to assess ventilator status at day 28. Participants discharged prior to day 28 (but not to home) on unassisted breathing will be assumed to remain on unassisted breathing through day 28. Isolated periods of ventilation briefer than 24 hours for surgical procedures and ventilation solely for sleep disordered breathing do not count towards duration of ventilation. In participants who never require assisted breathing, duration of ventilation is zero. Participants who do not survive 28 days will be assigned zero VFD.</description>
          <population>Excludes subjects who never required assisted breathing or who did not survive 28 days (considered zero vent free days).</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="11.3"/>
                    <measurement group_id="O2" value="22.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life by EuroQol (EQ-5D-5L)</title>
        <description>Changes in Quality of life score by EuroQol from baseline to day 90. Change was calculated as the value at day 90 minus the value at baseline. The EuroQol score is based on 5 dimensions of perceived problems: Mobility, Self-Care, Anxiety/Depression, Pain/discomfort, and Usual Activities. Problems with each area are assigned a level from 1-5 with level 1 being no problem and level 5 indicating extreme problems. A unique health state score is defined by combining 1 level from each of the 5 dimensions. Responses can be used to calculate a health utility score55 associated with the given health state that ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health).</description>
        <time_frame>baseline to study day 90</time_frame>
        <population>Subjects alive and able to be contacted at study day 90 and who had a baseline EQ-5D-5L assessment were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life by EuroQol (EQ-5D-5L)</title>
          <description>Changes in Quality of life score by EuroQol from baseline to day 90. Change was calculated as the value at day 90 minus the value at baseline. The EuroQol score is based on 5 dimensions of perceived problems: Mobility, Self-Care, Anxiety/Depression, Pain/discomfort, and Usual Activities. Problems with each area are assigned a level from 1-5 with level 1 being no problem and level 5 indicating extreme problems. A unique health state score is defined by combining 1 level from each of the 5 dimensions. Responses can be used to calculate a health utility score55 associated with the given health state that ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health).</description>
          <population>Subjects alive and able to be contacted at study day 90 and who had a baseline EQ-5D-5L assessment were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="-0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed (New) ARDS to Day 7</title>
        <description>Presence of ARDS determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio (i.e., imputed P/F ratio) and chest x-ray confirmation. PaO2 = partial pressure of arterial oxygen; FiO2 = percentage of inspired oxygen; SpO2 = peripheral capillary oxygen saturation, an estimate of the amount of oxygen in the blood. For participants with P/F &lt;300 or imputed P/F &lt;300, FiO2 ≥40%, and PEEP ≥5 cm H2O, we determined if hypoxemia was valid, acute, and not fully explained by congestive heart failure (CHF) or fluid overload. PEEP = positive end expiatory pressure.</description>
        <time_frame>Up to 7 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed (New) ARDS to Day 7</title>
          <description>Presence of ARDS determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio (i.e., imputed P/F ratio) and chest x-ray confirmation. PaO2 = partial pressure of arterial oxygen; FiO2 = percentage of inspired oxygen; SpO2 = peripheral capillary oxygen saturation, an estimate of the amount of oxygen in the blood. For participants with P/F &lt;300 or imputed P/F &lt;300, FiO2 ≥40%, and PEEP ≥5 cm H2O, we determined if hypoxemia was valid, acute, and not fully explained by congestive heart failure (CHF) or fluid overload. PEEP = positive end expiatory pressure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Acute Respiratory Distress Syndrome (ARDS)</title>
        <description>Severity of ARDS is determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio and confirmation of ARDS through chest x-ray reviews. The breakout of mild to severe was categorized as P/F or imputed P/F ratio of 201-300 (mild), 100-200 (moderate), or less than 100 (severe). This physiologic outcome is one of three key organ systems (respiratory, renal, and cardiovascular) used to assess change in organ failure severity from randomization up to study day 7.</description>
        <time_frame>7 days after randomization</time_frame>
        <population>Those subjects that developed new ARDS after randomization were analyzed for severity.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Acute Respiratory Distress Syndrome (ARDS)</title>
          <description>Severity of ARDS is determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio and confirmation of ARDS through chest x-ray reviews. The breakout of mild to severe was categorized as P/F or imputed P/F ratio of 201-300 (mild), 100-200 (moderate), or less than 100 (severe). This physiologic outcome is one of three key organ systems (respiratory, renal, and cardiovascular) used to assess change in organ failure severity from randomization up to study day 7.</description>
          <population>Those subjects that developed new ARDS after randomization were analyzed for severity.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mild ARDS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.0</ci_lower_limit>
            <ci_upper_limit>34.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate ARDS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-25.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-56.3</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Severe ARDS</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>41.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Acute Kidney Injury (AKI)</title>
        <description>This physiologic outcome is one of three key organ systems (respiratory, renal, and cardiovascular) used to assess change in organ failure severity from randomization up to study day 7. Worst AKI was determined by using highest daily creatinine values or new use of dialysis/ renal replacement therapy (chronic dialysis participants were excluded). Mild: On-study creatinine levels 1.5 times greater than baseline value or 0.3 mg/dL over the prehospital value. Moderate: On-study creatinine levels 2 times greater than the baseline pre-hospital value. Severe: On-study creatinine creatinine levels are 3 times greater than baseline prehospital value, or the on-study creatinine level is over 4 mg/dL with an acute (1 day) 0.5 mg/dL rise, or participant is on new renal replacement therapy.</description>
        <time_frame>Up to 7 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Worst Acute Kidney Injury (AKI)</title>
          <description>This physiologic outcome is one of three key organ systems (respiratory, renal, and cardiovascular) used to assess change in organ failure severity from randomization up to study day 7. Worst AKI was determined by using highest daily creatinine values or new use of dialysis/ renal replacement therapy (chronic dialysis participants were excluded). Mild: On-study creatinine levels 1.5 times greater than baseline value or 0.3 mg/dL over the prehospital value. Moderate: On-study creatinine levels 2 times greater than the baseline pre-hospital value. Severe: On-study creatinine creatinine levels are 3 times greater than baseline prehospital value, or the on-study creatinine level is over 4 mg/dL with an acute (1 day) 0.5 mg/dL rise, or participant is on new renal replacement therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No AKI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mild AKI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moderate AKI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Severe AKI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Renal Replacement Therapy (RRT)</title>
        <description>Participants who were on chronic dialysis at baseline were excluded from the analysis. Participants who started renal replacement therapy on a study day after day 0 and inclusive of day 7 were considered as having new renal replacement therapy. Those who have never started renal replacement therapy over days 0-7 were considered as not having new renal replacement therapy.</description>
        <time_frame>Up to 7 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>New Renal Replacement Therapy (RRT)</title>
          <description>Participants who were on chronic dialysis at baseline were excluded from the analysis. Participants who started renal replacement therapy on a study day after day 0 and inclusive of day 7 were considered as having new renal replacement therapy. Those who have never started renal replacement therapy over days 0-7 were considered as not having new renal replacement therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>2.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Creatinine Levels</title>
        <description>The highest recorded creatinine values is taken from available levels reported across the 7 study days for each patient.</description>
        <time_frame>Up to 7 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Creatinine Levels</title>
          <description>The highest recorded creatinine values is taken from available levels reported across the 7 study days for each patient.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="0.1"/>
                    <measurement group_id="O2" value="2.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Vasopressor Use to Day 7</title>
        <description>The number of subjects in each arm that are started on a vasopressor after randomization up to study day 7.</description>
        <time_frame>Up to 7 days after randomization</time_frame>
        <population>need info on this</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>New Vasopressor Use to Day 7</title>
          <description>The number of subjects in each arm that are started on a vasopressor after randomization up to study day 7.</description>
          <population>need info on this</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="360"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Cardiovascular SOFA (Sepsis Related Organ Failure Assessment) Score</title>
        <description>Cardiovascular score of the Organ SOFA score was used:
Score = 0: MAP* &gt;= 70 mmHg and No Drug;
Score = 1: MAP &lt; 70 mmHg and No Drug;
Score = 2: (Any MAP) ( dopamine&lt;=5 OR any dobutamine ) AND no other drugs (include neosynephrine vasopressin);
Score = 3: (Any MAP) 5 &lt; dopamine &lt;= 15 OR epinephrine &lt;= 0.1 OR norepinephrine &lt;= 0.1 OR neosynephrine &lt;=0.22 OR any dose vasopressin;
Score = 4: (Any MAP) dopamine &gt; 15 OR epinephrine &gt; 0.1 OR norepinephrine &gt; 0.1 OR neosynephrine &gt; 0.22
* MAP = mean arterial pressure</description>
        <time_frame>Up to 7 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Cardiovascular SOFA (Sepsis Related Organ Failure Assessment) Score</title>
          <description>Cardiovascular score of the Organ SOFA score was used:
Score = 0: MAP* &gt;= 70 mmHg and No Drug;
Score = 1: MAP &lt; 70 mmHg and No Drug;
Score = 2: (Any MAP) ( dopamine&lt;=5 OR any dobutamine ) AND no other drugs (include neosynephrine vasopressin);
Score = 3: (Any MAP) 5 &lt; dopamine &lt;= 15 OR epinephrine &lt;= 0.1 OR norepinephrine &lt;= 0.1 OR neosynephrine &lt;=0.22 OR any dose vasopressin;
Score = 4: (Any MAP) dopamine &gt; 15 OR epinephrine &gt; 0.1 OR norepinephrine &gt; 0.1 OR neosynephrine &gt; 0.22
* MAP = mean arterial pressure</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="523"/>
                <count group_id="O2" value="534"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.1"/>
                    <measurement group_id="O2" value="1.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25OHD Levels at Day 3</title>
        <description>Baseline levels will be measured using LC/MS/MS methods (all randomized participants) and at day 3 (the first 300 randomized participants only).</description>
        <time_frame>3 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>25OHD Levels at Day 3</title>
          <description>Baseline levels will be measured using LC/MS/MS methods (all randomized participants) and at day 3 (the first 300 randomized participants only).</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="23.2"/>
                    <measurement group_id="O2" value="11.4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>35.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.5</ci_lower_limit>
            <ci_upper_limit>39.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Total Calcium to Day 14</title>
        <description>Clinically available serum or ionized Ca levels were obtained through day 14 for all randomized patients. This time frame was selected to align with the 25OHD half life of two weeks.</description>
        <time_frame>14 days after randomization</time_frame>
        <population>Subjects with a clinically available total calcium level up to study day 14</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Total Calcium to Day 14</title>
          <description>Clinically available serum or ionized Ca levels were obtained through day 14 for all randomized patients. This time frame was selected to align with the 25OHD half life of two weeks.</description>
          <population>Subjects with a clinically available total calcium level up to study day 14</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="0.8"/>
                    <measurement group_id="O2" value="8.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Highest Ionized Calcium to Day 14</title>
        <description>Clinically available serum or ionized calcium levels through day 14 were collected for all randomized participants. This time frame was selected to align with the 25OHD half life of two weeks.</description>
        <time_frame>up to 14 days after randomization</time_frame>
        <population>Subjects with a clinically available ionized calcium level up to study day 14</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Highest Ionized Calcium to Day 14</title>
          <description>Clinically available serum or ionized calcium levels through day 14 were collected for all randomized participants. This time frame was selected to align with the 25OHD half life of two weeks.</description>
          <population>Subjects with a clinically available ionized calcium level up to study day 14</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="0.8"/>
                    <measurement group_id="O2" value="4.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypercalcemia to Day 14</title>
        <description>As the half-life of 25OHD is approximately 2 weeks, clinically available serum or ionized calcium levels through study day 14 were collected. The number of participants with hypercalcemia was reported.</description>
        <time_frame>up to 14 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Hypercalcemia to Day 14</title>
          <description>As the half-life of 25OHD is approximately 2 weeks, clinically available serum or ionized calcium levels through study day 14 were collected. The number of participants with hypercalcemia was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="513"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kidney Stones to Day 90</title>
        <description>Incident of kidney stones determined by chart review at the end of hospitalization and by self-report at day 90 phone call in those discharged from the hospital prior to day 90.</description>
        <time_frame>90 days after randomization</time_frame>
        <population>Subjects discharged from the hospital prior to study day 90.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Kidney Stones to Day 90</title>
          <description>Incident of kidney stones determined by chart review at the end of hospitalization and by self-report at day 90 phone call in those discharged from the hospital prior to day 90.</description>
          <population>Subjects discharged from the hospital prior to study day 90.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fall-related Fractures to Day 90</title>
        <description>Incident of fall-related fractures will be determined by chart review at the end of hospitalization and by self-report at day 90 phone call for those discharged from the hospital prior to day 90. Most data suggest that high dose vitamin D in healthy outpatients may improve muscle function, balance, and bone mineral density, and thus decrease fall-related fractures, but other data suggest that high dose vitamin D supplementation may actually increase the incidence of falls/fractures. Because of this uncertainty and limited data in hospitalized patients, we assessed for incident of fall-related fractures.</description>
        <time_frame>90 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Fall-related Fractures to Day 90</title>
          <description>Incident of fall-related fractures will be determined by chart review at the end of hospitalization and by self-report at day 90 phone call for those discharged from the hospital prior to day 90. Most data suggest that high dose vitamin D in healthy outpatients may improve muscle function, balance, and bone mineral density, and thus decrease fall-related fractures, but other data suggest that high dose vitamin D supplementation may actually increase the incidence of falls/fractures. Because of this uncertainty and limited data in hospitalized patients, we assessed for incident of fall-related fractures.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Falls to Day 90</title>
        <description>We assessed for incidence of falls by chart review at the end of hospitalization and by self-report at the 90 day phone call. Most data suggest that high dose vitamin D in healthy outpatients may improve muscle function, balance, and bone mineral density, and thus decrease fall-related fractures, but other data suggest that high dose vitamin D supplementation may actually increase the incidence of falls/fractures.</description>
        <time_frame>90 days post randomization</time_frame>
        <population>need to give info</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D Formulation</title>
            <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
          </group>
        </group_list>
        <measure>
          <title>Falls to Day 90</title>
          <description>We assessed for incidence of falls by chart review at the end of hospitalization and by self-report at the 90 day phone call. Most data suggest that high dose vitamin D in healthy outpatients may improve muscle function, balance, and bone mineral density, and thus decrease fall-related fractures, but other data suggest that high dose vitamin D supplementation may actually increase the incidence of falls/fractures.</description>
          <population>need to give info</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were assessed for adverse events from enrollment (signing of the informed consent) through study day 14 or hospital discharge, whichever occurs first. Investigators will determine if the event is serious or related to the study drug. The rationale for this time window is the 2 week half-life of 25OHD, which helps to define the period at risk from vitamin D.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Vitamin D Formulation</title>
          <description>A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
Vitamin D3: 540,000 IU vitamin D3</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="681"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="656"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="690"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Heparin Induced Thrombocytopenia and Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>PEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage Jejunum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>ED Visit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Readmission</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Readmission to MICU</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Weakness Left Sided</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>C Difficile Toxin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Colitis Pseudomembranous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Hearing Impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>CVA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Ureteral Calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Ureteral Obstruction from Renal Stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing Kussmaul Type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Lung Disease Obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Pulmonary Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrahge Retroperitoneal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Hypotension, Unresponsive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia Microcytic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Nausea and Vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Confidentiality</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelets Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Discoloration Urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="690"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="668"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="690"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="668"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>The Data and Safety Monitoring Board recommended that the trial be stopped at the first interim analysis when the primary outcome of the study crossed a protocol specified futility boundary. This adaptive design element resulted in a completed study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nancy Ringwood, CCC Project Manager</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9836</phone>
      <email>nringwood@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

